A study confirmed that the vaccines applied in Argentina generated a powerful cellular immune response

The data emerged from an investigation led by the CONICET scientist, Gabriel Rabinovich and applies to both homologous (same vaccine) and heterologous (combined doses) schemes. What the report says

Arg 1
The cellular immune response obtained with the vaccines applied in Argentina is powerful and robust (Ministerio de Salud CABA)

As revealed by recent research, the immune response at the cellular level with the vaccines applied in Argentina is powerful and robustwhether the schedules were with the same vaccine or with different vaccines.

It is a randomized, randomized scientific study carried out in the country, published by the Ministry of Health of the Nation and which concluded not to detect statistically significant differences between those who received a homologous vaccination (two doses of Sputnik V) and those who received a heterologous type (the first dose of Sputnik V, combined with another of the other vaccines available in the country).

The finding was possible thanks to the generation of the COVID-T Platform – unique in Latin America – designed and developed by Argentine scientists, with the aim of monitoring the antigen-specific T lymphocyte response in patients recovered from COVID-19 and in vaccinated people. The project arose within the framework of the Coronavirus Unit, promoted by the Ministry of Science, Technology, and Innovation, the National Council for Scientific and Technical Research (CONICET), and the National Agency for the Promotion of Research, Technological Development and Innovation(Agency I + D + i), and was presented and worked on by a team of scientists from the Institute of Biology and Experimental Medicine (IBYME – CONICET), led by the biochemist and Senior researcher of CONICET, Gabriel Rabinovich.

Arg 2
The Immune Response At The Cellular Level With The Vaccines Applied In Argentina Is Robust, Pointed Out From The Ministry Of Science And Health, Coronavirus Unit (Reuters / Athit Perawongmetha // File Photo)

The T lymphocyte reaction is very robust, both for CD4 and CD8 cell subpopulations, 14 days after vaccination. The immunogenic capacity of the vaccine is comparable in homologous and heterologous strategies”, described researcher Gabriel Rabinovich. CD4 T lymphocytes (cells) help coordinate the immune response by stimulating other cells of the immune system, such as macrophages, B lymphocytes, and CD8 T lymphocytes to fight SARS-CoV-2 infection in the body.

The Platform allows the study of the immune response of T lymphocytes, a type of immunity different from the one we analyze when evaluating the presence of antibodies, and its duration overtime against the SARS-CoV-2 virus in people who received one and two doses of the vaccines applied in Argentina, in this case, in the Province of Buenos Aires, in the Autonomous City of Buenos Aires and in patients recovered from the disease”, Explained the researcher. In this way, it is possible to comprehensively evaluate the immune response generated by the vaccines applied in Argentina. This project was inserted in the study also coordinated by the national Ministry of Health, which is carried out in the Provinces of Buenos Aires, Córdoba, La Rioja, and San Luis, called “Collaborative Study for the Evaluation of Heterologous Vaccination Schemes against COVID-19 in the Argentine Republic”.

Arg 3
Pfizer, Sputnik V, Astrazeneca And Moderna, Among The Inoculants Administered In Argentina (Reuters / Dado Ruvic / Illustration)

The work involved a large team of scientists, some of whom paused their original research in order to collaborate in the area of the emergency posed by the COVID-19 pandemic.

Complete vaccination = less mortality

A study carried out in the City of Buenos Aires among more than 660 thousand volunteers determined today that Sputnik V, AstraZeneca, and Sinopharm COVID-19 Vaccines “Significantly Reduce Morbidity and Mortality” from All Causes in People Over 60 Years Old. The research, signed by 8 experts, including the Buenos Aires Minister of Health, Fernán Quirós, was published last Friday by The Journal of the American Medical Association (JAMA) .

It is a “cohort study of 663,602 participants” that established that “COVID-19 vaccine use was associated with a significant reduction in death from all causes, COVID-related death and infection documented with the use of 1 dose and even more with the use of 2 doses,” the publication stated.

“These findings suggest that pragmatic use of available COVID-19 vaccines can significantly reduce morbidity and mortality,” Said the specialists who signed the research in the peer-reviewed scientific journal.

The study was released today by the Russian Direct Investment Fund (RDIF, Russia’s sovereign investment fund) to highlight the “high efficacy of the Russian vaccine in protecting people aged 60 years or older.”

Arg 4
Complete Vaccination Was Associated In Caba With A 96.6% Reduction In Mortality

The study included 663,602 people aged 60 years or older, vaccinated with Sputnik V, AstraZeneca, or Sinopharm, and residents of the city of Buenos Aires. Statistical analysis was performed from June 1 to June 15, 2021.

Most of the study participants, 63%, had been vaccinated with the full Sputnik V regimen, 25% received AstraZeneca, and 11.6% Sinopharm.

The results of the study show that the infection rate decreased by more than 88% among those who received the complete vaccination schedule against COVID-19 (that is, 2 doses for the three vaccines used). Complete vaccination was associated with a 96.6% reduction in mortality.

“This study found that within the first 5 months after the start of the vaccination campaign, the vaccination was associated with a significant reduction in COVID-19 infection, as well as a reduction in mortality”, Said the specialists in their conclusions.


Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

    Written by Christina d'souza

    Proofreader, editor, journalist. I have been doing my favourite thing for more than six years.

    Syndrome 6

    How is the campaign that seeks to create a real-time database on people with Down syndrome

    Insulin 1

    Controlling your insulin level reduces your risk of severe COVID-19